← Leaderboards
Michael D Roth
University Of California Los Angeles
$8,922,704
Attributed
$8,922,704
Total exposure
13
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2005–19$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$8,922,704 · 13
By mechanism
R01$6,904,427 · 4
N01$957,248 · 1
R21$943,972 · 2
R37$86,472 · 1
M01$30,585 · 3
P50$0 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Ziva D Cooper$11,236,541
- Adeline M Nyamathi$17,618,463
- Ruben J. Boado$14,771,226
- William M Pardridge$11,519,163
- Debika Bhattacharya$3,936,355
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsMacrophageReceptorLungResponseT-LymphocyteCytokineGrantClinical ResearchImmune ResponseMarijuana SmokingVirus DiseasesResearch PersonnelMediatingCannabinoid ReceptorHost DefenseCannabinoidsIn VivoImmuneIn VitroReceptor ExpressionBreathingAnimal ModelExposure To
Grant awards (30)
Marijuana smoke promotes dysfunctional macrophage responses to HIV and pneumonia$222,353
R01 · FY2019 · DA · contact PI
Marijuana smoke promotes dysfunctional macrophage responses to HIV and pneumonia$222,353
R01 · FY2018 · DA · contact PI
Marijuana smoke promotes dysfunctional macrophage responses to HIV and pneumonia$444,706
R01 · FY2017 · DA · contact PI
Marijuana smoke promotes dysfunctional macrophage responses to HIV and pneumonia$450,097
R01 · FY2016 · DA · contact PI
Marijuana smoke promotes dysfunctional macrophage responses to HIV and pneumonia$448,673
R01 · FY2015 · DA · contact PI
Marijuana smoke promotes dysfunctional macrophage responses to HIV and pneumonia$454,643
R01 · FY2014 · DA · contact PI
Pulmonary and Immunologic Effects of Marijuana Use on HIV and Viral Immunity$586,689
R01 · FY2010 · DA · contact PI
EVALUATING EFFECTS OF MARIJUANA SMOKING ABILITY TO RESPOND TO HEPATITIS B VACCIN$8,569
M01 · FY2010 · RR · contact PI
Pulmonary and Immunologic Effects of Marijuana Use on HIV and Viral Immunity$581,405
R01 · FY2009 · DA · contact PI
CYTOKINES AS PREDICTORS OF DISEASE PROGRESSION IN SCLERODERMA LUNG DISEASE$323,441
R01 · FY2009 · AR · contact PI
EVALUATING EFFECTS OF MARIJUANA SMOKING ABILITY TO RESPOND TO HEPATITIS B VACCIN$4,310
M01 · FY2009 · RR · contact PI
Pulmonary and Immunologic Effects of Marijuana Use on HIV and Viral Immunity$564,473
R01 · FY2008 · DA · contact PI
CYTOKINES AS PREDICTORS OF DISEASE PROGRESSION IN SCLERODERMA LUNG DISEASE$323,441
R01 · FY2008 · AR · contact PI
Pulmonary and Immunologic Effects of Marijuana Use on HIV and Viral Immunity$541,740
R01 · FY2007 · DA · contact PI
CYTOKINES AS PREDICTORS OF DISEASE PROGRESSION IN SCLERODERMA LUNG DISEASE$330,043
R01 · FY2007 · AR · contact PI
Vector-based Generation of Monoclonal Antibodies against the CB2 Receptor$147,190
R21 · FY2007 · DA · contact PI
COCAINE SMOKING EFFECTS ON THE LUNG IMMUNITY AND HOST DEFENSE: HIV$17,706
M01 · FY2007 · RR · contact PI
Cocaine Smoking Effects on Lung Immunity & Host Defense$488,175
R01 · FY2006 · DA · contact PI
EFFECTS OF MARIJUANA ON HIV AND VIRAL IMMUNITY$436,833
R01 · FY2006 · DA · contact PI
Vector-based Generation of Monoclonal Antibodies against the CB2 Receptor$165,211
R21 · FY2006 · DA · contact PI
PULMONARY EFFECTS OF HABITUAL USE OF MARIJUANA$86,472
R37 · FY2006 · DA · contact PI
Cocaine Smoking Effects on Lung Immunity &Host Defense$485,362
R01 · FY2005 · DA
Adjuvant immunotherapy for non-small cell lung cancer$316,725
R21 · FY2005 · CA
Adjuvant immunotherapy for non-small cell lung cancer$314,846
R21 · FY2004 · CA
Core--Clinical trials$0
P50 · FY2002 · CA
Career development program$0
P50 · FY2002 · CA
Core--Clinical trials$0
P50 · FY2001 · CA
Career development program$0
P50 · FY2001 · CA
CLINICAL CENTERS FOR FEASIBILITY STUDIES ON RETINOID TRE$817,243
N01 · FY2000 · HR
CLINICAL CENTERS FOR FEASIBILITY STUDIES ON RETINOID TRE$140,005
N01 · FY2000 · HR